Ensol Biosciences Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2017	FY 2016	FY 2015
Period Ending	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Net Income	-5,404	-6,067	-6,128
Depreciation & Amortization	398.38	406.16	344.91
Loss (Gain) From Sale of Assets	-1.48	-	-
Asset Writedown & Restructuring Costs	313.2	1,480	-
Loss (Gain) From Sale of Investments	-	-	19.93
Stock-Based Compensation	254.06	347.71	47.76
Provision & Write-off of Bad Debts	347.8	-	-
Other Operating Activities	291.55	150.59	3,835
Change in Accounts Receivable	-396.41	26.28	63.05
Change in Income Taxes	-4.23	1.36	-7.88
Change in Other Net Operating Assets	-452.27	223.5	-98.91
Operating Cash Flow	-4,653	-3,432	-1,924
Capital Expenditures	-142.78	-162.36	-629.68
Sale of Property, Plant & Equipment	1.48	-	-
Cash Acquisitions	-	-1,488	-
Sale (Purchase) of Intangibles	-50.98	-187.65	-148.09
Investment in Securities	2,616	-2,999	-1,520
Other Investing Activities	0	-	-
Investing Cash Flow	2,424	-4,837	-2,298
Short-Term Debt Issued	30	-	2,050
Total Debt Issued	30	-	2,050
Short-Term Debt Repaid	-	-1,680	-370
Long-Term Debt Repaid	-	-180	-3,090
Total Debt Repaid	-	-1,860	-3,460
Net Debt Issued (Repaid)	30	-1,860	-1,410
Issuance of Common Stock	-	6,996	5,599
Other Financing Activities	-	-10.8	-
Financing Cash Flow	30	5,125	10,187
Miscellaneous Cash Flow Adjustments	-0	-	-
Net Cash Flow	-2,200	-3,144	5,965
Free Cash Flow	-4,796	-3,595	-2,554
Free Cash Flow Margin	-892.34%	-2066.14%	-1264.32%
Free Cash Flow Per Share	-571.56	-436.04	-380.06
Cash Interest Paid	1.9	41.44	217.25
Levered Free Cash Flow	-3,263	-2,328	-
Unlevered Free Cash Flow	-3,261	-2,304	-
Change in Net Working Capital	293.18	-321.61	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.